



Oregon Prescription Drug Affordability Board (PDAB) Regular Meeting
Wednesday, October 15, 2025
Minutes approved by the board on Nov. 19, 2025

Web link to the meeting video: <https://youtu.be/pWLLdMtLE0A>

Web link to the meeting materials: <https://dfr.oregon.gov/pdab/Documents/20251015-PDAB-document-package.pdf>

Call to order: Chair Shelley Bailey called the meeting to order at 8:03 a.m. and roll was called.

Board members present: Chair Shelley Bailey, Vice Chair Amy Burns, Dan Hartung, Lauri Hoagland, Dan Kennedy, Michele Koder, John Murray. Chris Laman arrived at 8:21 a.m.

Absent: None

The board provided American Sign Language during the meeting.

Declaration of conflict of interest, meetings with entities or individuals related to board activities, or testifying before the Legislature: John Murray provided a statement. View at video minute [00:01:36](#).

Approval of board minutes: Chair Bailey asked for any corrections to the minutes of Aug. 20, 2025 and Sept. 17, 2025 on [Pages 3-7](#) and there were none. The chair approved the minutes by consensus, according to Robert's Rule of Order, which has been adopted by the board in [Policy 1](#). View at video minute [00:03:54](#).

Amendment to Oct. 15, 2025, board minutes from board member Lauri Hoagland: "I would like to amend my comments during the Oct. 15, 2025, board discussion. I did not articulate my concern regarding an audit of 340B pharmacies. I don't want to risk casting doubt on these programs at this time of health care austerity. From my experience working in a community clinic with a 340B pharmacy, many black and brown patients have access to medications that they would not otherwise as a result of 340B pricing. If we are going to consider equity, we need to understand the importance of this dispensing option for many vulnerable populations."

PDAB program update: Chair Bailey introduced Michele Koder, new board member, and Sarah Young, new executive director. Sarah Young provided a program update. View the video at minute [00:05:00](#).

General public comment: Chair Bailey called on the people who signed up in advance to speak to the board: Jessica McBride, Oregon Coalition for Affordable Prescriptions; Dharia McGrew, PhRMA; Lorren Sandt, Caring Ambassadors Program; Auden Friedman, OSPIRG; and Dean Suhr, MLD Foundation. The board received 15 written comments, which are posted on the [PDAB website](#). View the speakers at video minute [00:09:44](#).



Board continued discussion about policy recommendations for inclusion in the 2025 annual legislative report: Cortnee Whitlock, senior policy analyst, led the board in a continued discussion about the policy recommendations. View the proposed policies on [Pages 8-19](#). View the discussion at video minute [00:26:55](#).

Board continued review of methodology for drug reviews and scoring rubric and worksheet: Cortnee Whitlock, senior policy analyst, led the board in a discussion about the rubric and worksheet. View the documents on [Pages 6-12](#). View the discussion at video minute [01:32:19](#).

Drug review: Insulin Glargine - Basaglar KwikPen, Insulin Glargine-yfgn, Lantus, Lantus SoloStar, Semglee, Toujeo Max SoloStar, and Toujeo SoloStar: The board began discussions about drug reviews for insulin products. View the insulin glargine report on [Pages 32-65](#) posted on the PDAB website. View the discussion at video minute [02:22:11](#).

Drug review public comment periods: Chair Bailey announced the drug review public comment period and read the list of letters received regarding the insulin products under review. No one signed up to speak about insulin. See the table below for the list of public comment letters.

Announcements: Chair Bailey had to leave the meeting after the 10:30 am break and Vice Chair Amy Burns became acting chair. Vice Chair Amy Burns announced the next meeting will be Nov. 19, 2025, at 8 a.m. View at minute [03:21:02](#).

Adjournment: Vice Chair Amy Burns adjourned the meeting at 11:28 a.m. with all board members in agreement. View at minute [03:21:09](#).

Table of drug review public comment letters

Name of speaker	Association to drug under review	Drug	Format	Date	Exhibit website link
Carissa Kemp	Sanofi	Insulin glargine	Letter	6/17/25	Exhibit A
Cynthia Ransom	Eli Lilly	Basaglar	Letter	4/25/2025	Exhibit B
Carissa Kemp	Sanofi	Lantus	Letter	6/17/25	Exhibit C
Carissa Kemp	Sanofi	Toujeo	Letter	6/17/25	Exhibit D